The team will combine CellMax's circulating tumor cell platform and Medigen's liquid biopsy panel to track treatment response in colorectal cancer patients.
The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.
Under the five-year agreement extension, Quest will continue to provide broad access to Clinical Genomics's InSure One fecal immunochemical test in the US.
The firm plans to conduct a prospective trial of a pan cancer assay and aims to bring another assay focused on colorectal cancer through FDA clearance.
The measures are part of a long-term plan for the National Health Service that will be rolled out across the country to detect 3 out of every 4 cancers at an early stage.
